Sir, We have read with great interest the article by Arab-Alameddine et al.
1 on the pharmacokinetic analysis of different doses of darunavir. In their conclusions they stated that a standard 600/100 mg twice-daily regimen for treatment-experienced patients and 800/ 100 mg once daily for treatment-naive or treatment-experienced patients with limited resistance-associated mutations gave plasma concentrations that were within a safe margin with regard to the EC 50 for WT and resistant HIV-1 strains (where EC 50 is the concentration of a drug that gives a half-maximal response).
We would like to report our clinical experience in 26 HIVinfected patients treated with an 'unconventional' dose of darunavir (600 mg once daily). In our small cohort, 12 treatmentnaive patients (Group 1) received in addition tenofovir/emtricitabine (n¼ 9) or abacavir/lamivudine (n¼ 3); 7 experienced antiretroviral patients (Group 2, virologically suppressed, but switched, for different reasons, to 600/100 mg of darunavir/ritonavir once daily) received tenofovir/emtricitabine (n ¼ 2), abacavir/lamivudine (n ¼ 2), nevirapine (n ¼ 1) or zidovudine/lamivudine (n ¼ 1), while 1 patient received darunavir/ritonavir monotherapy; 7 experienced patients (Group 3) with a detectable viral load were switched to 600/100 mg of darunavir/ritonavir once daily with tenofovir/emtricitabine (n¼5), abacavir/lamivudine (n¼ 1) or raltegravir (n ¼ 1). All the patients gave their written informed consent. The patients' baseline characteristics are illustrated in Table 1 . Only one of the antiretroviral-experienced patients in whom a genotypic resistance test was performed had one darunavir-specific resistance mutation (Table 1) . Even though this patient was on a fosamprenavir-containing regimen before and had an I47V mutation, we opted for darunavir in view of the results of POWER studies 2 showing no reduced darunavir susceptibility in the presence of the I47V mutation. Of the 12 treatment-naive patients (Group 1; mean baseline HIV RNA 134 024 copies/mL, range 4526 -397 932 copies/mL), 11 had undetectable (,20 copies/mL) HIV RNA after a mean follow-up of 27.4 months (range 12 -33 months); the mean pharmacokinetic trough level was 2920 ng/mL (range 1268 -4562 ng/mL). Samples for pharmacokinetic analysis were collected 24 h after the last dose of darunavir. One patient had virological failure after 14 months (HIV RNA 39 300 copies/mL); no mutations were detected, and after introduction of 600/100 mg of darunavir/ritonavir twice daily he became aviraemic. All switched patients (Group 2) maintained HIV RNA suppression for a mean of 32.8 months (range 21 -54 months). The pharmacokinetic trough level was available for only one patient (C trough 3442 ng/mL). Of the treatment-experienced patients (Group 3; mean baseline HIV RNA 24 167 copies/mL, range 112 -111 426 copies/mL), five maintained HIV RNA suppression for a mean of 46.2 months (range 31 -67 months), one patient (harbouring the I47V resistance mutation) interrupted ART for 3 months and then restarted it (latest HIV RNA level 628 copies/mL after 5 weeks of therapy) and one patient failed after 42 months (HIV RNA 3930 copies/mL) and became aviraemic after intensification (600/100 mg of darunavir/ritonavir twice daily). Pharmacokinetic trough levels were available for three patients (mean 2502 ng/mL, range 844 -4518 ng/mL. Darunavir is a potent PI with a high genetic barrier that binds with very high affinity to HIV-1 protease and fits closely within the substrate envelope.
3 Darunavir (600 mg) boosted with lowdose ritonavir (100 mg) twice daily is effective and safe in treatment-experienced HIV-infected patients. 4 -6 Following the POWER trial 4 in treatment-experienced patients with PI resistance, 800/100 mg of darunavir/ritonavir once daily was selected for naive patients and the ARTEMIS trial confirmed its efficacy. 7 However, the results of POWER studies 2 found no correlation between the dose of darunavir/ritonavir and the efficacy, defined as at least a 1 log 10 reduction in HIV RNA from baseline at Week 24, for patients with low or no darunavir resistance at baseline (using an exploratory cut-off of fold change ,4, recommended by the regulatory authorities). It has been recently shown that a reduced dose of darunavir (600 mg once daily) in previously virologically suppressed patients is non-inferior to the standard dose (800 mg once daily) and darunavir concentrations in plasma and CSF are similar in patients receiving the different doses described above. 8, 9 In our clinical experience of 26 patients, the use of darunavir/ritonavir at a dose of 600/100 mg once daily led to sustained HIV RNA suppression in 23 patients with acceptable pharmacokinetic exposures to darunavir. This strategy could cut the cost of ART, thereby allowing more patients to be treated, even though it might be riskier for HIV-1 viraemic infected patients who have already failed a PIcontaining regimen. Large non-inferiority trials are warranted to establish the efficacy of lower doses of darunavir/ritonavir, as recently shown for efavirenz in the randomized, doubleblind, multicentre ENCORE study, 10 which demonstrated noninferiority of a 400 mg once-daily dose in respect of the standard 600 mg dose.
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Sir, Despite the use of potent and less-toxic drugs, NRTI exposure is associated with increasing reports of toxicity. 1, 2 In the search of alternatives, boosted PI monotherapy is not as effective as triple therapy, with a lower rate of viral suppression and increased intermittent viraemia (blips). 3 However, dual therapy with lamivudine plus a PI boosted with ritonavir has shown promising preliminary data 4, 5 and recently, lamivudine plus lopinavir/ritonavir twice daily has been shown to be non-inferior to triple therapy in naive patients. 6 This fact prompted us to prospectively assess from January 2011 to July 2013 the efficacy of a dual regimen with the combination of lamivudine plus darunavir/ritonavir (300 mg plus 800/100 mg, once daily), used after toxicity was experienced with NRTIs. No cases of pregnancy or chronic hepatitis B virus infection were included. No patient had evidence of resistance to darunavir or lamivudine or a previous history of virological failure. The study was approved by our institutional review board (EC 182/11) and patients gave written informed consent to clinical and analytical follow-up.
Routine physical examination and laboratory tests, including CD4+ cell counts and HIV-1 RNA levels [Versant HIV-1 RNA 1.0 Assay (kPCR), Siemens Diagnostics; limit of detection, 37 copies/mL], were performed at baseline and at every 3-4 months. The glomerular filtration rate (eGFR) was estimated at every analytical determination by the Chronic Kidney Disease Epidemiology Collaboration equation and urine analysis including measurements for protein, creatinine and glucose was performed at every visit. The primary study endpoint was the proportion of patients who were free of treatment failure during 48 weeks, defined as virological failure (HIV RNA level .37 copies/mL in two successive determinations), discontinuation of any drug or reintroduction of a three-drug regimen. Transient viral replication (blip) was defined as having an HIV RNA level .37 copies/mL not confirmed in a successive determination. At each timepoint, differences with respect to baseline were compared by the Wilcoxon rank test for paired samples. A twotailed P value of ,0.05 was considered statistically significant.
Overall, 48 patients were included and had .48 weeks of follow-up. The mean age of the patients was 50 years and 65% were male. Of note, patients had an undetectable HIV RNA level for a median time of 42 months (IQR 11.3-62.8) and showed a median nadir CD4+ count of 220 cells/mm 3 (IQR 101-312) and a median CD4+ count of 563 cells/mm 3 (IQR 399-795) at inclusion. Also, the majority of patients (30 cases, 63%) discontinued tenofovir from the NRTI backbone (8 interrupted didanosine, 7 abacavir and 3 other), mainly due to renal issues (25, 83%). Strikingly, only 10 patients were receiving darunavir as the third drug: 13 were receiving NNRTIs (3 etravirine, 3 nevirapine and 7 efavirenz) and 25 received another PI (9 atazanavir, 11 fosamprenavirand 5 lopinavir). Causes of switch varied widely according to the previous regimen.
All of the patients but one reached the study endpoint and had an undetectable HIV RNA level at 48+4 weeks. Thus, the efficacy
